SAMe and sexual functioning

C. M. Dording, D. Mischoulon, I. Shyu, Jonathan E. Alpert, G. I. Papakostas

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Background: Sexual dysfunction is a known side effect of antidepressant treatment (ADT), affecting up to 58-73% of those who receive ADT, potentially affecting antidepressant adherence. Consequently, it is vital to develop novel treatments that target antidepressant-induced sexual dysfunction. Methods: We examined whether adjunctive S-adenosyl-l-methionine (SAMe) is associated with greater improvement in sexual functioning than adjunctive placebo by measuring changes in sexual functioning using the Massachusetts General Hospital-Sexual Functioning Questionnaire (MGH-SFQ) during a 6-week, single-center, randomized, double-blind trial of SAMe augmentation for SSRI/SNRI- nonresponders. Results: Controlling for the degree of arousal dysfunction at baseline as well as the degree of change in HDRS-17 scale scores during the course of the study, men treated with adjunctive SAMe demonstrated significantly lower arousal dysfunction at endpoint than those treated with adjunctive placebo. In addition, controlling for the degree of erectile dysfunction at baseline as well as the degree of change in HDRS-17 scale scores, men treated with adjunctive SAMe demonstrated significantly lower erectile dysfunction at endpoint than those treated with adjunctive placebo. Conclusions: In the present study, we have observed that adjunctive SAMe can have positive benefit on male arousal and erectile dysfunction, independent of improvement in depressive symptoms. These findings are preliminary, and warrant replication. Clinical trials.gov identifier: NCT00093847; titled 'Optimizing the Effectiveness of Selective Serotonin Reuptake Inhibitors (SSRIs) in Treatment-Resistant Depression', accessible at: http://clinicaltrials.gov/ct2/show/. NCT00093847.

Original languageEnglish (US)
Pages (from-to)451-454
Number of pages4
JournalEuropean Psychiatry
Volume27
Issue number6
DOIs
StatePublished - Aug 2012
Externally publishedYes

Fingerprint

Methionine
Antidepressive Agents
Erectile Dysfunction
Arousal
Placebos
Serotonin Uptake Inhibitors
Treatment-Resistant Depressive Disorder
General Hospitals
Therapeutics
Clinical Trials
Depression

Keywords

  • Antidepressant-induced sexual dysfunction
  • Antidepressants
  • Major Depressive Disorder
  • S-adenosyl methionine
  • Side effects

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Dording, C. M., Mischoulon, D., Shyu, I., Alpert, J. E., & Papakostas, G. I. (2012). SAMe and sexual functioning. European Psychiatry, 27(6), 451-454. https://doi.org/10.1016/j.eurpsy.2011.01.003

SAMe and sexual functioning. / Dording, C. M.; Mischoulon, D.; Shyu, I.; Alpert, Jonathan E.; Papakostas, G. I.

In: European Psychiatry, Vol. 27, No. 6, 08.2012, p. 451-454.

Research output: Contribution to journalArticle

Dording, CM, Mischoulon, D, Shyu, I, Alpert, JE & Papakostas, GI 2012, 'SAMe and sexual functioning', European Psychiatry, vol. 27, no. 6, pp. 451-454. https://doi.org/10.1016/j.eurpsy.2011.01.003
Dording CM, Mischoulon D, Shyu I, Alpert JE, Papakostas GI. SAMe and sexual functioning. European Psychiatry. 2012 Aug;27(6):451-454. https://doi.org/10.1016/j.eurpsy.2011.01.003
Dording, C. M. ; Mischoulon, D. ; Shyu, I. ; Alpert, Jonathan E. ; Papakostas, G. I. / SAMe and sexual functioning. In: European Psychiatry. 2012 ; Vol. 27, No. 6. pp. 451-454.
@article{a6e2fdf4468b4dbaaf324c5fd8441862,
title = "SAMe and sexual functioning",
abstract = "Background: Sexual dysfunction is a known side effect of antidepressant treatment (ADT), affecting up to 58-73{\%} of those who receive ADT, potentially affecting antidepressant adherence. Consequently, it is vital to develop novel treatments that target antidepressant-induced sexual dysfunction. Methods: We examined whether adjunctive S-adenosyl-l-methionine (SAMe) is associated with greater improvement in sexual functioning than adjunctive placebo by measuring changes in sexual functioning using the Massachusetts General Hospital-Sexual Functioning Questionnaire (MGH-SFQ) during a 6-week, single-center, randomized, double-blind trial of SAMe augmentation for SSRI/SNRI- nonresponders. Results: Controlling for the degree of arousal dysfunction at baseline as well as the degree of change in HDRS-17 scale scores during the course of the study, men treated with adjunctive SAMe demonstrated significantly lower arousal dysfunction at endpoint than those treated with adjunctive placebo. In addition, controlling for the degree of erectile dysfunction at baseline as well as the degree of change in HDRS-17 scale scores, men treated with adjunctive SAMe demonstrated significantly lower erectile dysfunction at endpoint than those treated with adjunctive placebo. Conclusions: In the present study, we have observed that adjunctive SAMe can have positive benefit on male arousal and erectile dysfunction, independent of improvement in depressive symptoms. These findings are preliminary, and warrant replication. Clinical trials.gov identifier: NCT00093847; titled 'Optimizing the Effectiveness of Selective Serotonin Reuptake Inhibitors (SSRIs) in Treatment-Resistant Depression', accessible at: http://clinicaltrials.gov/ct2/show/. NCT00093847.",
keywords = "Antidepressant-induced sexual dysfunction, Antidepressants, Major Depressive Disorder, S-adenosyl methionine, Side effects",
author = "Dording, {C. M.} and D. Mischoulon and I. Shyu and Alpert, {Jonathan E.} and Papakostas, {G. I.}",
year = "2012",
month = "8",
doi = "10.1016/j.eurpsy.2011.01.003",
language = "English (US)",
volume = "27",
pages = "451--454",
journal = "European Psychiatry",
issn = "0924-9338",
publisher = "Elsevier Masson",
number = "6",

}

TY - JOUR

T1 - SAMe and sexual functioning

AU - Dording, C. M.

AU - Mischoulon, D.

AU - Shyu, I.

AU - Alpert, Jonathan E.

AU - Papakostas, G. I.

PY - 2012/8

Y1 - 2012/8

N2 - Background: Sexual dysfunction is a known side effect of antidepressant treatment (ADT), affecting up to 58-73% of those who receive ADT, potentially affecting antidepressant adherence. Consequently, it is vital to develop novel treatments that target antidepressant-induced sexual dysfunction. Methods: We examined whether adjunctive S-adenosyl-l-methionine (SAMe) is associated with greater improvement in sexual functioning than adjunctive placebo by measuring changes in sexual functioning using the Massachusetts General Hospital-Sexual Functioning Questionnaire (MGH-SFQ) during a 6-week, single-center, randomized, double-blind trial of SAMe augmentation for SSRI/SNRI- nonresponders. Results: Controlling for the degree of arousal dysfunction at baseline as well as the degree of change in HDRS-17 scale scores during the course of the study, men treated with adjunctive SAMe demonstrated significantly lower arousal dysfunction at endpoint than those treated with adjunctive placebo. In addition, controlling for the degree of erectile dysfunction at baseline as well as the degree of change in HDRS-17 scale scores, men treated with adjunctive SAMe demonstrated significantly lower erectile dysfunction at endpoint than those treated with adjunctive placebo. Conclusions: In the present study, we have observed that adjunctive SAMe can have positive benefit on male arousal and erectile dysfunction, independent of improvement in depressive symptoms. These findings are preliminary, and warrant replication. Clinical trials.gov identifier: NCT00093847; titled 'Optimizing the Effectiveness of Selective Serotonin Reuptake Inhibitors (SSRIs) in Treatment-Resistant Depression', accessible at: http://clinicaltrials.gov/ct2/show/. NCT00093847.

AB - Background: Sexual dysfunction is a known side effect of antidepressant treatment (ADT), affecting up to 58-73% of those who receive ADT, potentially affecting antidepressant adherence. Consequently, it is vital to develop novel treatments that target antidepressant-induced sexual dysfunction. Methods: We examined whether adjunctive S-adenosyl-l-methionine (SAMe) is associated with greater improvement in sexual functioning than adjunctive placebo by measuring changes in sexual functioning using the Massachusetts General Hospital-Sexual Functioning Questionnaire (MGH-SFQ) during a 6-week, single-center, randomized, double-blind trial of SAMe augmentation for SSRI/SNRI- nonresponders. Results: Controlling for the degree of arousal dysfunction at baseline as well as the degree of change in HDRS-17 scale scores during the course of the study, men treated with adjunctive SAMe demonstrated significantly lower arousal dysfunction at endpoint than those treated with adjunctive placebo. In addition, controlling for the degree of erectile dysfunction at baseline as well as the degree of change in HDRS-17 scale scores, men treated with adjunctive SAMe demonstrated significantly lower erectile dysfunction at endpoint than those treated with adjunctive placebo. Conclusions: In the present study, we have observed that adjunctive SAMe can have positive benefit on male arousal and erectile dysfunction, independent of improvement in depressive symptoms. These findings are preliminary, and warrant replication. Clinical trials.gov identifier: NCT00093847; titled 'Optimizing the Effectiveness of Selective Serotonin Reuptake Inhibitors (SSRIs) in Treatment-Resistant Depression', accessible at: http://clinicaltrials.gov/ct2/show/. NCT00093847.

KW - Antidepressant-induced sexual dysfunction

KW - Antidepressants

KW - Major Depressive Disorder

KW - S-adenosyl methionine

KW - Side effects

UR - http://www.scopus.com/inward/record.url?scp=84863871164&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863871164&partnerID=8YFLogxK

U2 - 10.1016/j.eurpsy.2011.01.003

DO - 10.1016/j.eurpsy.2011.01.003

M3 - Article

C2 - 21398094

AN - SCOPUS:84863871164

VL - 27

SP - 451

EP - 454

JO - European Psychiatry

JF - European Psychiatry

SN - 0924-9338

IS - 6

ER -